Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
Sponsored by Novo Nordisk A/S
About this trial
Last updated 8 years ago
Study ID
GHNOO-1658
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 20 years ago
What is this trial about?
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of
somatropin (Norditropin®) on final height in children with Noonan syndrome having being
treated for up to 10 years with somatropin (Norditropin®) for the attainment of an
optimal final height in the original trial S/GHD/004/NOO.
What are the participation requirements?
Inclusion Criteria
- Participation in the original S/GHD/004/NOO trial or following the protocol for S/GHD/004/NOO without being randomised in the trial